FIELD: chemistry.
SUBSTANCE: full-size human monoclonal antibodies against MCP-1 antigene are obtained. Antibodies are used for MCP-1 level definition in patient sample, as well as in tumour and inflammatory disease treatment. Invention allows obtainment of monoclonal antibodies highly specific to MCP-1 antigene.
EFFECT: efficient antibody use for treatment of the said diseases and in diagnostic purposes.
16 cl, 18 dwg, 17 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CXCR3 ANTIBODIES | 2013 |
|
RU2663141C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
| ANTI-PD-1 ANTIBODIES, METHOD FOR THEIR PRODUCTION, AND METHOD OF APPLICATION | 2016 |
|
RU2656181C1 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
